Estradiol down regulates expression of vasoactive intestinal polypeptide receptor type-1 in breast cancer cell lines

Molecular and Cellular Endocrinology

Volumn 172, Issue 1-2, 2001, Pages 203-211

  Madsen, B ^a   Georg, B ^a   Madsen, M W ^b   Fahrenkrug, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

Breast cancer cell lines; Estradiol; Gene regulation; Promoter activity; Vasoactive intestinal polypeptide receptor type 1

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CYCLOHEXIMIDE; DACTINOMYCIN; ESTRADIOL; FULVESTRANT; LUCIFERASE; MESSENGER RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FLANKING REGION; DOSE TIME EFFECT RELATION; DRUG INHIBITION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION;

5' UNTRANSLATED REGIONS; BINDING, COMPETITIVE; BREAST NEOPLASMS; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; PROMOTER REGIONS (GENETICS); RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0035857475     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(00)00341-5     Document Type: Article

References (47)

1. A simple method for the determination of affinity and binding site concentration in receptor binding studies
2. Improved survival among patient treated with adjuvant tamoxifen after mastectomy for early breast cancer
3. Functional expression of VIP receptors in normal immortalized and transformed mammary epithelial cells
4. Phenol red in culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture
5. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine
6. Single-step method of RNA isolation by acid guanidimurn thiocyanate-phenol-chloroform extraction
7. Human intestinal VIP receptor: cloning and functional expression of two cDNA proteins with different N-terminal domains
8. Evidence for estrogen receptor-mediated regulation of the human gonadotropin-releasing hormone promoter activity in human placental cells
9. Distribution and origin of peptide-containing nerve fibres in the rat and human mammary gland
10. The steroid and thyroid hormone receptor superfamily
11. Transcriptional regulation of expression of the rainbow trout albumin gene by estrogen
12. Sex steroid binding protein exerts a negative control on estradiol action in MCF-7 cells (human breast cancer) through cyclic adenosine 3′,5′-monophosphate and protein kinase A
13. Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappaB binding site in interleukin-6 promoter inhibition by estrogens
14. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cell
15. VIP molecular biology and neurobiological function
16. Nuclear receptors enhance our understanding of transcription regulation
17. Transcriptional regulation of hemoglobin switching in chicken embryo
18. Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing
19. Dibutyryl cyclic AMP treatment mimics ovariectomy: new genomic regulation in mammary tumor regression
20. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes
21. Vasoactive Intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor bearing human pancreatic adenocarcinoma-derived cells
22. Characterization of mechanisms of interieukin-6 gene repression by estrogen receptor
23. Estradiol 17-beta represses insulin-like growth factor I receptor expression in smooth muscle cells from rabbit cardiac recipients
24. Retinoic acid down-regulates the expression of the vasoactive intestinal polypeptide receptor type-1 in human breast carcinoma cell lines
25. Relationship of adenosine 3,5′-cyclic monophosphate and guanosine 3′,5′-cyclic monophosphate to growth of dimethylbenz[a]antracene-induced mammary tumors in rat
26. VIP and breast cancer
27. 21)VIP: evaluation of biological activity and localization to breast cancer tumors
28. Estrogen modulates AT1 receptor gene expression in vitro and in vivo
29. Characterization of the rat vasoactive intestinal polypeptide receptor gene 5′-region
30. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts
31. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
32. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implication for tumor imaging
33. Oestrogen- and anti-oestrogen-regulated genes in human breast cancer
34. Expression and regulation of retinoic acid receptors in human breast cancer cells
35. The effects of dibutyryl cAMP on enzymatic and metabolic changes in explants of rat mammary tissue
36. Stimulation of tumor cell growth by vasoactive intestinal peptide
37. Pituitary adenylate cyclase activating polypeptide (PACAP) in the rat mammary gland
38. Structure, expression and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene
39. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor
40. Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts
41. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic ANW analogues
42. A potent specific pure antiestrogen with clinical potential
43. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines
44. High levels of vasoactive intestinal peptide in human milk
45. Vasoactive intestinal peptide: a growth promotor in neuroblastoma cells
46. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist